Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Hepatocellular Carcinoma: Immunotherapy After Sorafenib 

Recent Advances in the Treatment of Liver Cancer 

Interventional Radiology and More for HCC

Locoregional Therapies for Extrahepatic HCC

Managing Locoregional Therapies in HCC

Growing Treatment Landscape in Liver Cancer

Novel Combinations on the Horizon in HCC

Emerging Second-Line Therapies in HCC

Frontline Clinical Trials in Liver Cancer

Sequencing Considerations in HCC

HCC: Nivolumab's Side Effects

Proactive Management of TKI Side Effects in HCC

HCC: Considerations in Toxicity Management

Second-Line Nivolumab in Liver Cancer

Response and Outcomes With TKIs in HCC

HCC: Multidisciplinary Decision-Making

Trends and Risk Factors in Liver Cancer

Pembrolizumab (Keytruda) induced responses in more than one-fifth of patients with recurrent thymic carcinoma who had progressed following 1 or more lines of chemotherapy. 

Pembrolizumab Active in Thymic Carcinoma

George R. Simon, MD, discusses emerging advancements with immunotherapy combination strategies for patients with NSCLC.

Simon Shares Insight on Emerging Immunotherapy Regimens in NSCLC

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a novel prognostic marker for patients with advanced bladder cancer being treated with the PD-L1 inhibitor atezolizumab (Tecentriq).
 

Dr. Sonpavde on Novel Prognostic Marker for Atezolizumab in Bladder Cancer

Immuno-Oncology

Immuno-Oncology | Specialty